# ARWR

Arrowhead Pharmaceuticals (ARWR) is experiencing significant social media buzz around its CNS delivery breakthroughs in RNAi therapeutics, with discussions highlighting potential valuation increases and buyout prospects amidst a competitive landscape.

### About ARWR
ARWR is a cryptocurrency project focused on decentralized finance and blockchain innovation, though recent social media activity primarily discusses its pharmaceutical endeavors in RNAi therapeutics.  

### Engagements: [------] (24h)
![Engagements Line Chart](https://lunarcrush.com/gi/w:600/t:arwr/c:line/m:interactions/iv:1d.svg)  
[Engagements 24-Hour Time-Series Raw Data](/topic/arwr/time-series/interactions.tsv)  
Current Value: [------]  
Daily Average: [------]  
[--] Month: [-------] -71%  
[--] Months: [---------] +230%  
[--] Year: [----------] +97%  
1-Year High: [-------] on 2025-11-25  
1-Year Low: [--] on 2025-05-31  

Engagements by network (24h):
TikTok: [--]
X: [------]
YouTube: [--]
Reddit: [--]

  
  
### Mentions: [---] (24h)
![Mentions Line Chart](https://lunarcrush.com/gi/w:600/t:arwr/c:line/m:posts_active/iv:1d.svg)  
[Mentions 24-Hour Time-Series Raw Data](/topic/arwr/time-series/posts_active.tsv)  
Current Value: [---]  
Daily Average: [---]  
[--] Month: [--] no change  
1-Year High: [-----] on 2025-11-28  
1-Year Low: [--] on 2025-05-31  

Mentions by network (24h):
TikTok: [--]
X: [---]
YouTube: [--]
Reddit: [--]

  
  
### Creators: [---] (24h)
![Creators Line Chart](https://lunarcrush.com/gi/w:600/t:arwr/c:line/m:contributors_active/iv:1d.svg)  
[Creators 24-Hour Time-Series Raw Data](/topic/arwr/time-series/contributors_active.tsv)  
[---] unique social accounts have posts mentioning ARWR in the last [--] hours which is up 51% from [---] in the previous [--] hours
Daily Average: [---]  
[--] Month: [--] no change  
1-Year High: [---] on 2025-11-28  
1-Year Low: [--] on 2025-05-31  

The most influential creators that mention ARWR in the last [--] hours

| Creator                                | Rank | Followers | Posts | Engagements |
| -------                                | ---- | --------- | ----- | ----------- |
| [@Tickeron](/creator/twitter/Tickeron) | [--]    | [------]    | [--]     | [--]          |

[View More](/list/creators/arwr/100)
  
  
### Sentiment: 84%
![Sentiment Line Chart](https://lunarcrush.com/gi/w:600/t:arwr/c:line/m:sentiment/iv:1d.svg)  
[Sentiment 24-Hour Time-Series Raw Data](/topic/arwr/time-series/sentiment.tsv)  
Current Value: 84%  
Daily Average: 78%  
[--] Month: 71% -3%  
[--] Months: 71% -19%  
[--] Year: 71% no change  
1-Year High: 100% on 2025-03-16  
1-Year Low: 17% on 2025-03-20  

Most Supportive Themes:
- CNS Delivery Breakthrough: (40%) Posts highlight ARWR's potential for CNS delivery of RNAi therapeutics, with evidence of crossing the blood-brain barrier and achieving deep brain-wide knockdown in non-human primates. This is seen as a modality-level disruption with significant implications for treating neurological diseases.
- RNAi Platform Innovation: (30%) The discussion centers on ARWR's RNAi platform, emphasizing its scalability and safety record. The ability to selectively turn down harmful proteins without permanently altering DNA is a key advantage, positioning RNAi as a powerful tool for restorative medicine.
- Market Valuation and Buyout Potential: (20%) Several posts suggest that successful CNS delivery could double ARWR's valuation and make it a legitimate buyout target. The company's progress in RNAi therapeutics is attracting significant investor attention.
  
Most Critical Themes:
- Competition in RNAi Space: (70%) While ARWR is making strides, there's an underlying theme of competition from other RNAi players and pharmaceutical giants. Deals and partnerships involving competitors like Alnylam and Sanegenebio are noted, indicating a dynamic and crowded market.
- Clinical Trial Data and Validation: (30%) The success of ARWR's platform hinges on consistent clinical trial data, particularly regarding CNS target engagement. Comparisons are drawn to competitors' studies, highlighting the importance of upcoming data releases for validation.
  

### Top ARWR Social Posts
Top posts by engagements in the last [--] hours

*Showing a maximum of [--] top social posts without a LunarCrush subscription.*

"$ARWR Is Arrowhead Pharmaceuticals (ARWR) Pricing Reflect Recent RNAi Progress And Strong Share Price Gains - #stocks #news http://simplywall.st http://simplywall.st"  
[X Link](https://x.com/StockTickerZone/status/2019273018782917067) [@StockTickerZone](/creator/x/StockTickerZone) 2026-02-05T04:52Z [----] followers, [---] engagements


"Ciena Set to Join S&P 500; Arrowhead Pharmaceuticals to Join S&P MidCap 400; ADT and OneSpaWorld Holdings to Join S&P SmallCap [---] $CIEN $DAY $ARWR $ADT $OSW $DVAX $SNY https://www.crweworld.com/article/news-provided-by-pr-newswire/3785718/ciena-set-to-join-sampp-500-arrowhead-pharmaceuticals-to-join-sampp-midcap-400-adt-and-onespaworld-holdings-to-join-sampp-smallcap-600 https://www.crweworld.com/article/news-provided-by-pr-newswire/3785718/ciena-set-to-join-sampp-500-arrowhead-pharmaceuticals-to-join-sampp-midcap-400-adt-and-onespaworld-holdings-to-join-sampp-smallcap-600"  
[X Link](https://x.com/CrweWorld/status/2019230734784086407) [@CrweWorld](/creator/x/CrweWorld) 2026-02-05T02:04Z [----] followers, [---] engagements


"@jonesallen99138 CNS delivery isnt double for $ARWR conservatively its at least a [--] platform rerate. I already value Arrowhead at $41B with CNS in the base case. Prove consistent brain target engagement and the market has to price a true multi-tissue #RNAi platform. https://x.com/i/status/1998966758410170379 1/10 Just went through $ARWRs CNS Delivery Summit deck and holy knockdown Batman Arrowhead just casually showed SC-delivered RNAi crossing the BBB with deep brain-wide knockdown in NHPs. This isnt incremental science this is modality-level disruption."  
[X Link](https://x.com/BioBoyScout/status/2019222369022407124) [@BioBoyScout](/creator/x/BioBoyScout) 2026-02-05T01:31Z [----] followers, [----] engagements


"@jonesallen99138 $srpt $arwr Which study would you guess will publish CNS PK/PD/engagement data first INSIGHTT/Study SRP-1005-101 or AROMAPT-SC-1001 https://clinicaltrials.gov/study/NCT07221344term=Arrowhead&sort=StudyFirstPostDate&limit=10&page=1&rank=4 https://clinicaltrials.gov/study/NCT07221344term=Arrowhead&sort=StudyFirstPostDate&limit=10&page=1&rank=4"  
[X Link](https://x.com/Hall8Jack/status/2019213953994486030) [@Hall8Jack](/creator/x/Hall8Jack) 2026-02-05T00:58Z [----] followers, [----] engagements

Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing